Virax Biolabs Group (VRAX) Competitors $1.04 -0.10 (-8.33%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. BCTX, CARM, COCP, SLGL, MEIP, IMNN, SYBX, LPTX, NRSN, and IXHLShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include BriaCell Therapeutics (BCTX), Carisma Therapeutics (CARM), Cocrystal Pharma (COCP), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Imunon (IMNN), Synlogic (SYBX), Leap Therapeutics (LPTX), NeuroSense Therapeutics (NRSN), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. BriaCell Therapeutics Carisma Therapeutics Cocrystal Pharma Sol-Gel Technologies MEI Pharma Imunon Synlogic Leap Therapeutics NeuroSense Therapeutics Incannex Healthcare BriaCell Therapeutics (NASDAQ:BCTX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability. Do institutionals & insiders hold more shares of BCTX or VRAX? 15.4% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 5.7% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend BCTX or VRAX? BriaCell Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 801.41%. Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 188.46%. Given BriaCell Therapeutics' higher possible upside, analysts plainly believe BriaCell Therapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BriaCell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in BCTX or VRAX? BriaCell Therapeutics received 11 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. CompanyUnderperformOutperformBriaCell TherapeuticsOutperform Votes12100.00% Underperform VotesNo VotesVirax Biolabs GroupOutperform Votes1100.00% Underperform VotesNo Votes Which has higher earnings and valuation, BCTX or VRAX? BriaCell Therapeutics has higher earnings, but lower revenue than Virax Biolabs Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriaCell TherapeuticsN/AN/A-$4.79M-$5.03-0.71Virax Biolabs Group$84.87K39.62-$6.73MN/AN/A Does the media favor BCTX or VRAX? In the previous week, Virax Biolabs Group had 5 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 6 mentions for Virax Biolabs Group and 1 mentions for BriaCell Therapeutics. Virax Biolabs Group's average media sentiment score of 0.60 beat BriaCell Therapeutics' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BriaCell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Virax Biolabs Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BCTX or VRAX more profitable? Company Net Margins Return on Equity Return on Assets BriaCell TherapeuticsN/A N/A -191.19% Virax Biolabs Group N/A N/A N/A Which has more risk & volatility, BCTX or VRAX? BriaCell Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. SummaryBriaCell Therapeutics and Virax Biolabs Group tied by winning 5 of the 10 factors compared between the two stocks. Remove Ads Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.36M$2.39B$5.58B$7.57BDividend YieldN/A0.74%5.35%4.04%P/E RatioN/A6.1022.9818.19Price / Sales39.6241.24362.8486.44Price / CashN/A15.7538.1634.64Price / Book0.522.906.534.03Net Income-$6.73M-$65.73M$3.21B$247.18M7 Day Performance-16.13%-6.12%-5.84%-5.61%1 Month Performance-34.59%-11.89%-0.12%-6.72%1 Year Performance19.54%-27.08%6.42%-3.53% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.1246 of 5 stars$1.05-8.3%$3.00+187.1%+45.4%$3.38M$84,872.000.005Analyst ForecastShort Interest ↓Analyst RevisionGap UpBCTXBriaCell Therapeutics1.2498 of 5 stars$4.46-0.2%$32.00+617.5%-91.2%$16.54MN/A-0.338News CoverageGap DownCARMCarisma Therapeutics2.9974 of 5 stars$0.39-4.8%$4.94+1,154.8%-88.9%$16.44M$20.27M-0.2520Upcoming EarningsAnalyst ForecastNews CoverageGap DownCOCPCocrystal Pharma3.2051 of 5 stars$1.58+1.3%$7.00+343.0%-3.4%$16.08MN/A-0.8510Earnings ReportAnalyst RevisionNews CoverageSLGLSol-Gel Technologies2.7116 of 5 stars$0.57+9.7%$5.00+776.6%-53.0%$15.89M$11.71M-1.6850Positive NewsGap DownMEIPMEI Pharma3.8359 of 5 stars$2.35+2.2%$7.00+197.9%-46.3%$15.66M$65.30M-0.41100Analyst ForecastGap DownIMNNImunon1.9776 of 5 stars$1.07+12.1%$20.50+1,824.9%-40.0%$15.57M$500,000.00-0.5630SYBXSynlogicN/A$1.29-0.7%N/A-31.8%$15.10M$8,000.00-0.3180Gap DownLPTXLeap Therapeutics2.4964 of 5 stars$0.39-2.7%$4.92+1,160.7%-87.1%$14.94MN/A-0.2040Short Interest ↓Analyst RevisionGap DownNRSNNeuroSense Therapeutics0.3505 of 5 stars$1.08+0.9%N/A-50.1%$14.76MN/A-1.6910Upcoming EarningsGap DownIXHLIncannex Healthcare0.3632 of 5 stars$0.80-3.5%N/A-80.9%$14.29M$98,000.00-0.583News CoverageGap Up Remove Ads Related Companies and Tools Related Companies BriaCell Therapeutics Competitors Carisma Therapeutics Competitors Cocrystal Pharma Competitors Sol-Gel Technologies Competitors MEI Pharma Competitors Imunon Competitors Synlogic Competitors Leap Therapeutics Competitors NeuroSense Therapeutics Competitors Incannex Healthcare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
